Key result
Novel polymeric transcatheter valve shows favorable hemodynamics and acceptable safety at 1 year in AS.
Why the study?
Does the Sikelia transcatheter heart valve with polymeric leaflets demonstrate safety and improve hemodynamics in patients with severe symptomatic aortic stenosis?
Does the Sikelia transcatheter heart valve with polymeric leaflets demonstrate safety and improve hemodynamics in patients with severe symptomatic aortic stenosis?
In a first-in-human study, the novel Sikelia transcatheter heart valve with polymeric leaflets demonstrated early safety, feasibility, and excellent hemodynamic performance at 1 year for severe aortic stenosis.
Answers are grounded in this paper and cite their sources.
Early feasibility data for polymeric TAVR; leaves open durability and randomized comparisons.
BACKGROUND: Transcatheter aortic valve replacement is a promising alternative treatment for patients with severe aortic stenosis (AS), but uncertainties remain regarding its long-term durability. OBJECTIVES: This study aimed to evaluate the safety and feasibility of Sikelia transcatheter heart valve with polymeric leaflets in AS. METHODS: In this first-in-human, prospective, nonrandomized, single-arm, multicenter study, patients with severe symptomatic AS eligible for the novel valve were recruited. Clinical outcomes and hemodynamic performance were reported at discharge and 30-day, 6-month, and 1-year follow-up. RESULTS: ) and mean pressure gradient (6.33 ± 2.54 mm Hg vs 47.50 ± 13.82 mm Hg) improved substantially, so did those in bicuspid patients (all P < 0.001). No moderate/severe paravalvular leakage was recorded, and computed tomography scans revealed no evidence of subclinical leaflet thrombosis during follow-up. After discharge, no patients reported death, stroke, new pacemakers, or valve-related reintervention. CONCLUSIONS: The preliminary outcomes of the novel transcatheter heart valve demonstrated a favorable hemodynamic performance with an acceptable safety profile at 1 year. Long-term follow-up is warranted to assess its durability in treating patients with AS.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied severe symptomatic aortic stenosis. Sikelia transcatheter heart valve with polymeric leaflets was evaluated on mean pressure gradient (p=< 0.001). The Sikelia transcatheter heart valve with polymeric leaflets substantially improved mean pressure gradient with no death, stroke, or reintervention at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: